Ultragenyx Pharmaceutical Inc.
RARE
$26.84
$0.542.05%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -2.16% | 25.89% | 14.65% | 13.24% | 27.72% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.16% | 25.89% | 14.65% | 13.24% | 27.72% |
| Cost of Revenue | -0.57% | 13.44% | 27.77% | 2.71% | -11.23% |
| Gross Profit | -5.71% | 37.29% | -63.20% | 40.59% | 59.86% |
| SG&A Expenses | -1.15% | 7.39% | 7.80% | 7.50% | 11.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.48% | 11.71% | 21.86% | 4.18% | 2.85% |
| Operating Income | 2.80% | 7.38% | -29.47% | 7.28% | 13.52% |
| Income Before Tax | -22.67% | 3.86% | -34.78% | 12.80% | 11.88% |
| Income Tax Expenses | 0.00% | 126.56% | 188.12% | 10.37% | 119.78% |
| Earnings from Continuing Operations | -22.52% | 3.49% | -35.12% | 12.65% | 11.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.52% | 3.49% | -35.12% | 12.65% | 11.53% |
| EBIT | 2.80% | 7.38% | -29.47% | 7.28% | 13.52% |
| EBITDA | 2.24% | 7.33% | -31.69% | 7.66% | 14.38% |
| EPS Basic | -17.28% | 7.56% | -29.33% | 23.19% | 22.57% |
| Normalized Basic EPS | 1.72% | 8.00% | -28.83% | 20.92% | 24.54% |
| EPS Diluted | -17.28% | 7.56% | -29.33% | 23.19% | 22.57% |
| Normalized Diluted EPS | 1.72% | 8.00% | -28.83% | 20.92% | 24.54% |
| Average Basic Shares Outstanding | 4.47% | 4.41% | 4.48% | 13.72% | 14.25% |
| Average Diluted Shares Outstanding | 4.47% | 4.41% | 4.48% | 13.72% | 14.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |